

WHAT IS CLAIMED IS:

1. A composition, comprising  
a substance having a function of decreasing a reduced glutathione content in at  
least one cell selected from the group consisting of macrophages, monocytes and  
5 dendric cells, as an active ingredient.

2. The composition according to claim 1, wherein the substance can reduce the  
glutathione content by at least 30% when incubated in vitro with macrophages for from  
1 to 24 hours.

10

3. The composition according to claim 1, wherein the substance is at least one  
member selected from the group consisting of a N, N'-diacylcystine, N, N'-  
diacylcystine ester, busulfan, L-S, R-buthionine sulfoximine, R-buthionine sulfoximine  
derivative and a maleic acid diester.

15

4. The composition according to claim 1, wherein the substance is an organ  
transplant rejection suppressor.

5. The composition according to claim 4, wherein the organ is at least one  
20 member selected from the group consisting of liver, lung, kidney, liver, heart, skin,  
cornea, and corneal epithelium.

6. The composition according to claim 4, wherein the organ is a part of at least one member selected from the group consisting of liver, lung, kidney, liver, heart, skin, cornea, and corneal epithelium.

5           7. The composition according to claim 4, wherein the rejection is mainly a rejection to a minor antigen.

8. The composition according to claim 4, wherein the organ is at least one member selected from the group consisting of a cornea and corneal epithelium.

10

9. A pharmaceutical composition, comprising the composition according to claim 1 and a pharmaceutically acceptable carrier.

10. The pharmaceutical composition according to Claim 9, wherein the  
15 composition is in at least one form selected from the group consisting of an oral drug, eye drop and infusion.

11. A method of decreasing a reduced glutathione content in at least one cell selected from the group consisting of macrophages, monocytes and dendric cells,  
20 comprising

administering the composition according to Claim 1 to the at least one cell.

12. A food, drink or nutriment preparation, comprising the composition according to Claim 1.

13. A method of suppressing, alleviating, reducing, treating, and retarding transplant rejection in a subject, comprising administering the composition according to Claim 1 to the subject.

5

14. The method according to Claim 13, wherein the subject is a mammal.

15. The method according to Claim 14, wherein the mammal is a human.

10        16. The method according to Claim 13, wherein the substance is administered in at least one form selected from the group consisting of an oral drug, eye drop and infusion.

15        17. The method according to Claim 13, wherein the substance is administered in at least one form selected from the group consisting of a pharmaceutical, food, drink and nutriment.

18. The method according to Claim 13, wherein the composition is administered at a dose ranging from at least once a day to at least once every 5 days.

20

19. The method according to Claim 13, wherein the composition is administered at a dose ranging from 1 mg to 10 g.

20. A method of making a composition, comprising contacting a substance having a function of decreasing a reduced glutathione content in at least one cell selected from the group consisting of macrophages, monocytes and dendric cells, as an active ingredient and a pharmaceutically acceptable carrier.

5